Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ZyVersa Therapeutics, Inc. - Common Stock (NQ:ZVSA)

0.6460 -0.0440 (-6.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ZyVersa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in A.G.P.’s Virtual Healthcare Conference
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference
From ZyVersa Therapeutics
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 345 companies set new 52-week lows. 
Via Benzinga
Crude Oil Down 3%; Boeing Reports Better-Than-Expected Sales
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 150 points on Wednesday. The Dow traded down 0.49% to 33,366.74 while the NASDAQ rose 0.75% to 11,887.81. The S&P... 
Via Benzinga
Why Chipotle Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 105% to $0.1730 after the company issued a letter to shareholders. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Edges Lower; Alphabet Posts Upbeat Results
U.S. stocks traded mixed midway through trading, with the Dow Jones turning lower on Wednesday. The Dow traded down 0.11% to 33,492.84 while the NASDAQ rose 1.16% to 11,936.00. The S&P 500, also rose,... 
Via Benzinga
Why Is Enphase Energy (ENPH) Stock Down 19% Today?
Enphase Energy (ENPH) stock is falling hard on Wednesday following the release of its earnings report for the first quarter of 2023. 
Via InvestorPlace
ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public Offering
From ZyVersa Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Is Bed Bath & Beyond (BBBY) Stock Down 24% Today?
Bed Bath & Beyond (BBBY) stock is falling on Wednesday as the company's recent bankruptcy announcement weighs on its shares. 
Via InvestorPlace
Why Is ZyVersa Therapeutics (ZVSA) Stock Down 46% Today?
ZyVersa Therapeutics (ZVSA) stock is sliding lower on Wednesday following a couple of announcements from the biopharmaceutical company. 
Via InvestorPlace
Why Bed Bath & Beyond Shares Are Trading Lower By 23%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers that investors need to know about on Wednesday morning! 
Via InvestorPlace
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment. 
Via Benzinga
ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100
From ZyVersa Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV
Via ACCESSWIRE
Why Bed Bath & Beyond Shares Are Trading Lower By Around 38%; Here Are 20 Stocks Moving Premarket
Gainers ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) gained 118% to $3.64 in pre-market trading after declining around 5% on Friday. ZyVersa Therapeutics recently posted a wider FY loss. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with the biggest pre-market stock movers that traders will want to keep an eye on for Monday morning! 
Via InvestorPlace
ZyVersa: This Drug Maker Is Targeting Critical Diseases With Novel Approaches
Steve Glover, Co-Founder, Chairman, CEO, & President of ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA), was recently a guest on Benzinga’s All-Access. 
Via Benzinga
ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics’ CEO, Stephen C. Glover to Appear on Benzinga 'All Access'
From ZyVersa Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.